Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;25(2):127-136.
doi: 10.1111/jch.14632. Epub 2023 Jan 20.

Fixed-dose combination therapy-based protocol compared with free pill combination protocol: Results of a cluster randomized trial

Affiliations

Fixed-dose combination therapy-based protocol compared with free pill combination protocol: Results of a cluster randomized trial

Olutobi A Sanuade et al. J Clin Hypertens (Greenwich). 2023 Feb.

Abstract

Fixed-dose combination (FDC) therapy is recommended for hypertension management in Nigeria based on randomized trials at the individual level. This cluster-randomized trial evaluates effectiveness and safety of a treatment protocol that used two-drug FDC therapy as the second and third steps for hypertension control compared with a protocol that used free pill combinations. From January 2021 to June 2021, 60 primary healthcare centers in the Federal Capital Territory of Nigeria were randomized to a protocol using FDC therapy as second and third steps compared with a protocol that used the same medications in free pill combination therapy for these steps. Eligible patients were adults (≥18 years) with hypertension. The primary outcome was the odds of a patient being controlled at their last visit between baseline to 6-month follow-up in the FDC group compared to the free pill group. 4427 patients (mean [SD] age: 49.0 [12.4] years, 70.5% female) were registered with mean (SD) baseline systolic/diastolic blood pressure 155 (20.6)/96 (13.1) mm Hg. Baseline characteristics of groups were similar. After 6-months, hypertension control rate improved in the two treatment protocols, but there were no differences between the groups after adjustment (FDC = 53.9% versus free pill combination = 47.9%, cluster-adjusted p = .29). Adverse events were similarly low (<1%) in both groups. Both protocols improved hypertension control rates at 6-months in comparison to baseline, though no differences were observed between groups. Further work is needed to determine if upfront FDC therapy is more effective and efficient to improve hypertension control rates.

Trial registration: ClinicalTrials.gov NCT04158154.

Keywords: Nigeria; cluster-randomized trial; fixed-dose combination; free pill combination; hypertension.

PubMed Disclaimer

Conflict of interest statement

MDH has pending patents for heart failure polypills. George Health Enterprises Pty Ltd (GH) and its subsidiary, George Medicines Pty Ltd, have received investment funds to develop fixed‐dose combination products, including combinations of blood pressure‐lowering drugs. GH is the social enterprise arm of The George Institute for Global Health. Other co‐authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
(A) Hypertension control rate (95% CI), defined as blood pressure <140/<90 mm Hg at the last visit by treatment protocol for patients who visited a primary healthcare center at least twice from baseline to 6 months. Protocol 1‐ Free pill combination protocol; Protocol 2‐ Fixed‐dose combination therapy. (B) Hypertension control rate (95% CI), defined as blood pressure <140/<90 mmHg at the last visit by treatment protocol for patients who visited a primary healthcare center at least twice from baseline to 6 months. Protocol 1‐ Free pill combination protocol; Protocol 2‐ Fixed‐dose combination therapy.
FIGURE 2
FIGURE 2
(A) Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline to 6‐month follow‐up, stratified by treatment protocol. (B) Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline to 6‐month follow‐up, stratified by treatment protocol for patients who visited their PHC at least twice.

References

    1. Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population‐based studies from 90 countries. Physiol Behav. 2017;176:139‐148. - PMC - PubMed
    1. Salam A, Huffman MD, Kanukula R, et al. Two‐drug fixed‐dose combinations of blood pressure‐lowering drugs as WHO essential medicines: an overview of efficacy, safety, and cost. J Clin Hypertens. 2020;22:1769‐1779. - PMC - PubMed
    1. Benjamin IJ, Kreutz R, Olsen MH, et al. Fixed‐dose combination antihypertensive medications. Lancet. 2019;394:637‐638. - PubMed
    1. Odili AN, Chori BS, Danladi B, et al. Prevalence, awareness, treatment and control of hypertension in Nigeria: data from a nationwide survey 2017. Glob Heart. 2020;15:47‐59. - PMC - PubMed
    1. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the european society of hypertension (ESH) and of the European society of cardiology (ESC). Eur Heart J. 2013;34:2159‐2219. - PubMed

Publication types

Associated data